The new Access to Medicine Index

The Lancet

Volumn 372, Issue 9642, 2008, Pages 891-

  Ali, Mohammed K ^a   Narayan, KM Venkat ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN;

DEVELOPING COUNTRY; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; LETTER; LOWEST INCOME GROUP; PRIORITY JOURNAL; SOCIAL BEHAVIOR;

EID: 51449101291     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61396-3     Document Type: Letter

References (5)

1. Decker S., and Pettypiece S. Pfizer, Ranbaxy delay generic Lipitor for 20 months (June 18, 2008). http://www.bloomberg.com (accessed July 28, 2008).
2. McNeil D.G.J. Index ranks pharmaceutical groups according to third world outreach. The New York Times (June 17, 2008)
3. Mendis S., Fukino K., Cameron A., et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ 85 (2007) 279-288
4. Prahalad C.K. The fortune at the bottom of the pyramid: eradicating poverty through profits (2006), Wharton School Publishing, Upper Saddle River 265-286
5. Friedman M.A., den Besten H., and Attaran A. Out-licensing: a practical approach for improvement of access to medicines in poor countries. Lancet 361 (2003) 341-344